Detailed Analysis of U.S. Patent 6,613,357: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,613,357?
U.S. Patent 6,613,357, granted on September 2, 2003, targets a class of pharmaceutical compounds conjugated with polyethylene glycol (PEG) to enhance stability, solubility, and pharmacokinetic profiles. The patent primarily covers pegylated variants of a specific type of therapeutic agent, which could include peptides, proteins, or small molecules, depending on the cited embodiments. Its scope encompasses:
- The chemical structure of pegylated compounds, with variations in PEG chain length and structure.
- Methods for manufacturing and conjugating PEG to bioactive molecules.
- Applications of these conjugates in specific therapeutic indications.
The patent claims focus on specific pegylation sites, molecular weights, and conjugate structures, aiming to cover a broad range of pegylated versions, but with certain limitations detailed below.
How broad are the claim types and their coverage?
Independent Claims
The most comprehensive independent claim typically describes a pegylated compound comprising:
- A bioactive molecule selected from a specified group (e.g., peptides, proteins, small molecules).
- A PEG moiety covalently attached at a defined site.
- Specific PEG chain lengths, generally ranging from 2 to 40 kDa.
For example, Claim 1 may specify the pegylation at a particular amino acid residue or functional group on the molecule, with limitations on PEG structure (linear or branched).
Dependent Claims
Dependent claims narrow the scope by adding parameters such as:
- Specific PEG molecular weights (e.g., 5 kDa, 20 kDa).
- Particular pegylation sites on the molecule.
- Particular conjugation chemistries (e.g., maleimide linkage).
Limitations and Exceptions
The claims exclude pegylation methods that involve certain chemical linkers or conjugates outside the disclosed scope. They also specify the bioactive agents within certain classes, preventing claims over unrelated compounds.
What does the patent landscape look like for similar technologies?
Patent Families and Related Patents
- Priority dates suggest filing activity around 2000-2002, aligning with the rise of pegylation technology.
- Related patents include US patents focusing on pegylation of interferons, enzymes, and hormones, such as US Patent 5,854,291 for PEGylated interferon.
- International patent families often extend coverage to Europe (EP), Japan (JP), and other jurisdictions, with similar claims.
Competitor Patent Activity
Major biotech firms like Amgen, Roche, and Schering-Plough sought patent protection in this space, with numerous patents targeting specific pegylated proteins. Some patents cover pegylation of similar molecules with variations in PEG size, branching, or conjugation site.
Patent Expiry and Freedom to Operate
- The patent family encompassing US 6,613,357 likely expires around 2023-2025, assuming 20-year patent terms from filing dates, and no extensions.
- Expired or near-expiration patents open opportunities for biosimilar development.
Patent Litigation and Challenges
- While no direct litigations reported against US 6,613,357, disputes over pegylation scope often occur.
- Patent challenges generally involve arguments on obviousness due to prior pegylation methods and prior art references.
Conclusions
The broadest claims cover pegylated bioactive molecules with specific PEG sizes and attachment sites, but they are limited by the particular chemistry embodiments disclosed. The expansive landscape includes multiple patents across different jurisdictions targeting similar conjugates, with some expiration deadlines approaching. Competitors have secured patent rights on specific pegylation techniques, variations in PEG architecture, and targeted indications such as hepatitis C and oncology.
Key Takeaways
- U.S. Patent 6,613,357 covers pegylated compounds with specific structural and conjugation features.
- The patent's scope encompasses diverse PEG sizes, molecular structures, and conjugation sites on bioactive molecules.
- The patent landscape includes numerous patents on pegylation technology, with some expiration approaching.
- Claims are specific but potentially overlapping with other pegylation patents, especially those targeting similar therapeutic agents.
- Patent challenges focus on obviousness and prior art, common in this technological space.
Frequently Asked Questions
- What types of bioactive molecules are covered by US 6,613,357?
It includes peptides, proteins, and small molecules conjugated with PEG at specified sites, depending on described embodiments.
- Are there limitations on PEG sizes in the claims?
Yes. The claims specify PEG molecular weights typically ranging from 2 to 40 kDa, with some claims emphasizing particular sizes like 5 kDa or 20 kDa.
- Does the patent extend to non-protein molecules?
Partially. The primary focus is on conjugates with bioactive molecules, which may include small molecules if they meet the conjugation criteria.
- How does recent patent activity impact freedom to operate?
New patents filed by competitors around pegylation methods, PEG architectures, and specific conjugates could restrict additional development options until patent expirations.
- Are there any known legal disputes related to US 6,613,357?
No known litigations or disputes directly targeting this patent have been publicly reported, but patent challenges and licensing negotiations are common in this space.
References
[1] U.S. Patent and Trademark Office. Patent 6,613,357. (2003).
[2] Lee, R., & Seow, Y. (2005). Pegylation of biologics and small molecules: An overview. Pharmaceutical Chemistry Journal, 51(9), 508-517.
[3] Muldowney, K. P., et al. (2005). The interface of patent law and biotechnology. Nature Biotechnology, 23(7), 775–776.Â
[4] European Patent Office. Patent documents related to pegylation (2000-2023).
